These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31781900)

  • 41. Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma?
    Dorcaratto D; Udupa V; Hogan NM; Brophy DP; McCann JW; Maguire D; Geoghegan J; Cantwell CP; Hoti E
    Diagn Interv Radiol; 2017; 23(6):441-447. PubMed ID: 29063856
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial.
    Vogl TJ; Lammer J; Lencioni R; Malagari K; Watkinson A; Pilleul F; Denys A; Lee C
    AJR Am J Roentgenol; 2011 Oct; 197(4):W562-70. PubMed ID: 21940527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
    Chen P; Yuan P; Chen B; Sun J; Shen H; Qian Y
    Clin Res Hepatol Gastroenterol; 2017 Feb; 41(1):75-85. PubMed ID: 27350573
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres
    Zhang X; Lin X; Qiu H; Peng Z
    J Clin Lab Anal; 2019 Oct; 33(8):e22975. PubMed ID: 31328832
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
    Ludwig JM; Zhang D; Xing M; Kim HS
    Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients.
    Farid K; Elalfy H; Abo El-Khair SM; Elgamal H; Besheer T; Elmokadem A; Shabana W; Abed S; Elegezy M; El-Khalek AA; El-Morsy A; Negm A; Elsamanoudy AZ; El Deek B; Amer T; El-Bendary M
    Expert Rev Gastroenterol Hepatol; 2020 Dec; 14(12):1203-1214. PubMed ID: 32933325
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study.
    Zhao C; Yan H; Xiang Z; Wang H; Li M; Huang M
    Invest New Drugs; 2023 Aug; 41(4):617-626. PubMed ID: 37434023
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma.
    Facciorusso A; Mariani L; Sposito C; Spreafico C; Bongini M; Morosi C; Cascella T; Marchianò A; Camerini T; Bhoori S; Brunero F; Barone M; Mazzaferro V
    J Gastroenterol Hepatol; 2016 Mar; 31(3):645-53. PubMed ID: 26331807
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
    Varela M; Real MI; Burrel M; Forner A; Sala M; Brunet M; Ayuso C; Castells L; Montañá X; Llovet JM; Bruix J
    J Hepatol; 2007 Mar; 46(3):474-81. PubMed ID: 17239480
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
    Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
    Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemoembolization Adopting Polyethylene Glycol Drug-Eluting Embolics Loaded With Doxorubicin for the Treatment of Hepatocellular Carcinoma.
    Aliberti C; Carandina R; Sarti D; Mulazzani L; Pizzirani E; Guadagni S; Fiorentini G
    AJR Am J Roentgenol; 2017 Aug; 209(2):430-434. PubMed ID: 28537756
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma.
    Korsic S; Levasic N; Dezman R; Zupan LAL; Trotovsek B; Jansa R; Smid A; Popovic P
    Radiol Oncol; 2022 Aug; 56(3):311-318. PubMed ID: 35535426
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma.
    Cucchetti A; Trevisani F; Cappelli A; Mosconi C; Renzulli M; Pinna AD; Golfieri R
    Dig Liver Dis; 2016 Jul; 48(7):798-805. PubMed ID: 27263056
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
    Bi Y; Ren K; Ren J; Ma J; Han X
    Front Pharmacol; 2022; 13():923585. PubMed ID: 36034827
    [No Abstract]   [Full Text] [Related]  

  • 55. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
    Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
    Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma: does size really matter?
    Lee SY; Ou HY; Yu CY; Huang TL; Tsang LL; Cheng YF
    Diagn Interv Radiol; 2020 May; 26(3):230-235. PubMed ID: 32352922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE).
    Peisen F; Maurer M; Grosse U; Nikolaou K; Syha R; Ketelsen D; Artzner C; Bitzer M; Horger M; Grözinger G
    Eur Radiol; 2020 Jul; 30(7):3782-3792. PubMed ID: 32125515
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma.
    Bi Y; Wang Y; Zhang W; Lu H; Ren J; Han X
    Cancer Imaging; 2023 Feb; 23(1):19. PubMed ID: 36814327
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
    J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads.
    Cascella T; Garanzini EM; Lanocita R; Morosi C; Riva F; Greco G; Sposito C; Mazzaferro V; Marchianò A; Spreafico C
    Cardiovasc Intervent Radiol; 2022 Jan; 45(1):54-61. PubMed ID: 34820694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.